Pfizer releases positive Phase IV results with crisaborole

US pharma giant Pfizer (NYSE:PFE) saw its shares rise more than 1% to $43.77 by close of trading on Monday, after it announced top-line results from a Phase IV study (CrisADe CARE 1) which showed that crisaborole ointment, 2%, was well-tolerated in children aged three months to less than 24 months with mild to moderate atopic dermatitis (AD), also known as eczema.

The data from the trial are supportive of the primary study objective to examine the safety of crisaborole ointment, 2%, in this patient population, and are consistent with previous clinical trial experience.

Crisaborole ointment, 2%, is currently approved in select countries for mild to moderate AD in patients two years of age and older. Pfizer gained rights to the product along with its $5.2 billion acquisition of Anacor Pharmaceuticals in2016.